The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
REGULATORY
Kobayashi Kako Submits Report on Drug Mix-Up, Could Face Administrative Penalty in 1st Half of February
Japanese authorities could issue an administrative penalty to Kobayashi Kako in the first half of February after the generic maker submitted a report on January 20 over a sleep-inducer contamination found in its antifungal drug itraconazole. In early December, Kobayashi…
To read the full story
Related Article
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- 4 APIs/9 Products Excluded from Kobayashi Kako Biz Suspension for Medical Needs
February 24, 2021
- Kobayashi Kako Chief to Resign over Drug Mix-Up, Lousy Manufacturing and Cover-Ups
February 10, 2021
- Kobayashi Kako Expelled from JGA over Drug Mix-Up
February 10, 2021
- Kobayashi Kako Slapped with Record 116-Day Business Suspension
February 9, 2021
- Regulators to Issue Biz Suspension Order to Kobayashi Kako on Feb. 9
February 8, 2021
- Kobayashi Kako Might Face 116-Day Biz Suspension over Drug Mix-Up
January 27, 2021
- Kobayashi Kako Notified of Record Biz Suspension of 110-Plus Days over Drug Mix-Up
January 26, 2021
- Kobayashi Kako Expected to Face Administrative Penalty This Fiscal Year, Biz Suspension Likely
January 12, 2021
- First Time FPMAJ’s Supply Coordination Scheme Invoked for 13 APIs Tied to Kobayashi Kako
January 5, 2021
- Kobayashi Kako Adds 2 APIs to Class II Recall List, Meiji/Elmed Products
December 28, 2020
- Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
December 25, 2020
- Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
December 24, 2020
- 2nd Death Reported for Tainted Itraconazole User, Doctor Says Causal Link Unlikely
December 18, 2020
- Kobayashi Kako Manually Managed Itraconazole Production; Hand-Written Record on Rilmazafone Mix-Up Found
December 17, 2020
- Kobayashi Kako Temporary Halts Shipments of All Products after Tainted Itraconazole Issue
December 15, 2020
- 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
- Kobayashi Kako Recalls Trigger Shipment Control for Kaken's Itraconazole Product
December 11, 2020
- Pharmacist Group Chief Appalled at Itraconazole Recalls; 84 Cases of Health Damages Reported
December 10, 2020
- With Contaminated Itraconazole, Patients Might Have Taken Sleep Inducer at 10-20 Times Regular Dosage
December 9, 2020
- Kobayashi Kako Launches Another Recall for Itraconazole, Class II This Time
December 8, 2020
- Kobayashi Kako Recalls Itraconazole over Hypnotic Contamination; Side Effects Confirmed
December 7, 2020
REGULATORY
- Imfinzi, 2 Other Drugs under PMDA Safety Review
March 8, 2021
- Japan Speeds Up Vaccine Delivery for HCPs, Kono Says All 2nd Doses to Reach Municipalities in 1st Half of May
March 8, 2021
- MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
- Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
- Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…